-
2025-521314-25-00
5
2026-03-19
NPM1-m and KMT2A-r Acute Myeloid Leukemia
-
2025-521884-12-00
5
2026-03-19
First line triple-negative breast cancer (TNBC)
-
2024-519555-28-00
5
2026-03-18
Dravet syndrome
-
2024-519537-29-00
1
2026-03-13
Acute Myeloid Leukemia and Myelodysplastic Syndrome
-
2025-520805-10-00
5
2026-03-12
Chronic inflammatory demyelinating polyneuropathy (CIDP)
-
2024-516476-15-00
9
2026-03-04
Advanced gastrointestinal stromal tumor (GIST)
-
2024-519579-24-00
5
2026-02-26
Classic Congenital Adrenal Hyperplasia
-
2025-522033-64-00
1
2026-02-26
Myelofibrosis
-
2025-522553-19-00
10
2026-02-25
Symptomatic genetic and familial dilated cardiomyopathy.
-
2024-520353-21-00
3
2026-02-24
Myeloproliferative Neoplasms
-
2024-520098-12-00
4
2026-02-16
Cutaneous Lupus Erythematosus
-
2024-520200-26-00
4
2026-02-13
Inherited anemias
-
2024-519068-42-00
10
2026-02-12
Heterozygous Familial Hypercholesterolemia in pediatric patients
-
2024-518777-34-00
5
2026-02-11
B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
-
2025-521514-26-00
5
2026-01-26
Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer W
-
2025-521852-45-00
4
2026-01-22
Cutaneous T-Cell Lymphoma
-
2025-520766-22-00
5
2026-01-21
Myotonic Dystrophy Type 1
-
2025-521352-38-00
5
2026-01-16
Hereditary Angioedema
-
2024-520097-36-00
5
2026-01-07
Chronic inflammatory demyelinating polyneuropathy (CIDP)
-
2022-501607-27-00
7
2026-01-06
Relapsed or refractory B-cell Non-Hodgkin lymphoma
-
2024-511508-18-00
9
2026-01-05
Chronic graft versus host disease.
-
2025-522052-13-00
10
2025-12-24
Framework for Optimizing, Refining, and Unifying Management of HSCT in
-
2023-507525-42-00
5
2025-12-23
Endometrial cancer
-
2022-503140-41-00
5
2025-12-19
Melanoma